Understand the source comparison
VIP Before and After: Research Design Comparison
Single-dose acute (0–24h) 0h, 6h, 24h Serum cytokines, receptor binding, cAMP levels High. Captures immediate signaling Ideal for receptor pharmacology and acute signaling studies; misses phenotypic shifts Multi-dose short (7–14d) 0d, 3d, 7d, 14d Cytokines, im
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Single-dose acute (0–24h)
- 0h, 6h, 24h
- Serum cytokines, receptor binding, cAMP levels
- High. Captures immediate signaling
- Ideal for receptor pharmacology and acute signaling studies; misses phenotypic shifts
- Multi-dose short (7–14d)
- 0d, 3d, 7d, 14d
- Cytokines, immune cell phenotypes, functional assays
- Moderate. Shows therapeutic window
- Standard for immunomodulation research; captures peak efficacy before desensitization
- Extended intervention (21–28d)
- 0d, 7d, 14d, 21d, 28d
- Tissue histology, structural markers, long-term function
- High. Reveals chronic effects
- Required for tissue remodeling and neuroprotection; high risk of receptor downregulation
- Prophylactic dosing
- −7d, 0d (challenge), 3d, 7d
- Disease scores, immune activation markers, tissue damage
- High. Tests prevention vs treatment
- Best for autoimmune models where VIP prevents rather than reverses inflammation
- Endpoint-only (0d, 28d)
- 0d, 28d
- Final outcomes only
- None. Correlational data
- Insufficient for publication; provides no mechanistic insight into temporal dynamics